Prognostic value of Muc5AC in gastric cancer: A meta-analysis

Table 1 Characteristics of the included studies

No.	Ref.	Year	Area	No. of patients	Gender M/F	Medium age	Therapy before surgical resection	Antibody used	Cut-off value	Purpose
1	Baldus et al[23]	2002	Germany	200	107/93	60.8	No	CLH2	35%	C/HR
2	Dae et al[25]	2013	South Korea	412	286/126	58.5	No	CLH2	10%	HR
3	Ilhan et al[24]	2010	Turkey	257	201/56	NR	No	45M1	5%	C
4	Kocer et al[16]	2004	Turkey	44	31/13	59.75	No	45M1	10%	C/HR
5	Lee et al[26]	2001	South Korea	300	203/97	NR	NR	CLH2	20%	C
6	Shiratsu et al[27]	2013	Japan	214	150/64	NR	No	CLH2	5%	C/HR
7	Suh et al[17]	2012	South Korea	450	328/122	57.5	No	NR	10%	HR
8	Sung et al[12]	2013	South Korea	412	286/126	58.5	No	CLH2	5%	C
9	Tajima et al[28]	2001	Japan	136	82/54	61.7	No	45M1	10%	C
10	Wang et al[18]	2003	China	76	52/24	65.0	NR	45M1	5%	C/HR
11	Wang et al[29]	2003	China	46	34/12	54.6	NR	45M1	0%	C

NR: Not reported; M: Male; F: Female; C: Clinicopathological characteristics; HR: Hazard ratio.